News
Stephenson Harwood advises Bicycle Therapeutics on radiotherapy deal with Bayer
Law firm Stephenson Harwood LLP has advised Bicycle Therapeutics plc on its recent strategic collaboration agreement with Bayer to discover and develop Bicycle radioconjugates for multiple…
Stephenson Harwood advises Bicycle Therapeutics on radiopharmaceuticals deal with Novartis
Law firm Stephenson Harwood LLP has advised Bicycle Therapeutics on its recent strategic collaboration agreement with Novartis to discover and develop multiple targeted radioligand therapies in…
Stephenson Harwood's response to recent news regarding Silicon Valley Bank
Having spent the weekend supporting clients reacting to the bank's potential collapse in the UK, Stephenson Harwood is pleased to hear the latest news this morning concerning HSBC's rescue of the…
Stephenson Harwood advises Oxford Biomedica on new AstraZeneca agreement
Law firm Stephenson Harwood LLP has advised Oxford Biomedica, the gene and cell therapy company, on its new three year Master Services & Development Agreement with AstraZeneca UK Ltd (…
Kristian Shearsby joins Stephenson Harwood as partner
Law firm Stephenson Harwood LLP has strengthened its corporate finance practice, and life sciences and technology sector capabilities, with the arrival of Kristian Shearsby as partner in its…
Stephenson Harwood advises Apposite Capital on Emblation investment
Law firm Stephenson Harwood LLP has advised healthcare investor Apposite Capital on its investment in medical device company, Emblation.
Stephenson Harwood advises e-therapeutics plc on £22.5 million fundraise
Law firm Stephenson Harwood LLP has advised e-therapeutics plc on a fundraise of £22.5 million.
Stephenson Harwood advises GE Healthcare on transformative Zionexa acquisition
Law firm Stephenson Harwood LLP has advised GE Healthcare on the acquisition of Zionexa. GE Healthcare is a medical technology, pharmaceutical diagnostics, and digital solutions company; Zionexa…
Partner Alexandra Pygall joins Babraham Institute Board
Stephenson Harwood partner Alexandra Pygall has been appointed to The Babraham Institute’s Board of Trustees.
Stephenson Harwood advises Acacia Pharma on €27 million fundraise
Law firm Stephenson Harwood LLP has advised Acacia Pharma Group plc on its successful €27 million fundraise, through the placing of 10 million new ordinary shares with institutional investors in…
Stephenson Harwood advises Schroder UK Public Private Trust on £49 million asset sale
Law firm Stephenson Harwood LLP has acted for Schroder UK Public Private Trust plc (SUPP) on an agreement for the £49 million sale of seven portfolio assets to Rosetta Capital VI, LP, an…
Stephenson Harwood advises Oxford Biomedica on gene therapy collaboration
Law firm Stephenson Harwood LLP has advised gene and cell therapy company Oxford Biomedica on its collaboration with biopharmaceutical company PhoreMost, to develop next-generation CAR-T cell…
Stephenson Harwood advises capiton on KD Pharma single-asset secondary
Law firm Stephenson Harwood LLP has advised private equity firm capiton on a general partner-led single asset secondary transaction relating to the KD Pharma Group.
Stephenson Harwood advises Oxford Biomedica on COVID-19 vaccine with AstraZeneca
Law firm Stephenson Harwood LLP has advised Oxford Biomedica plc (Oxford Biomedica), a gene and cell therapy company, on a Clinical and Commercial Supply Agreement with AstraZeneca UK Ltd (…